|
|
ProBioGen and Minapharm
Pharmaceuticals join forces
to create MiGenTra GmbH - A
Healthcare Transforming
Medicines Company
(Berlin,
Germany and Cairo,
Egypt) --
ProBioGen and
Minapharm Pharmaceuticals
announce the incorporation
of ProBioGen's subsidiary
"MiGenTra" with headquarters
in Berlin and access to a
site in Cairo, which will
house its principal
manufacturing plant. The
formation of MiGenTra
accelerates ProBioGen's 2030
growth roadmap and showcases
that further growth is not
limited to the ongoing
capacity increase but
reveals one of several
significant steps in the
diversification of
ProBioGen's business.
MiGenTra will enhance
the accessibility to
critical healthcare
transforming medicines at
affordable prices for Egypt,
the Middle East and Africa
(MEA) while simultaneously
strengthening regional and
local manufacturing
capacities. The company will
respond to urgent unmet
medical needs, supporting
efforts by the World Health
Organization (WHO) and the
International Finance
Corporation (IFC).
MiGenTra combines the
scientific and manufacturing
expertise from both
contributing companies,
ProBioGen and Minapharm
Pharmaceuticals. It is
established for product
development and
commercialization in the
field of Biosimilars, Cell
and Gene Therapies (CGT) and
vaccines, capitalizing on
the strong development
capabilities of ProBioGen
and the excellent market
position of Minapharm in the
region.
"Healthcare
is not a privilege but a
human right", says Lutz
Hilbrich, MD MBA, and Chief
Executive Officer of
ProBioGen. He continues: "By
creating MiGenTra we
exemplify our commitment to
overcome inequalities.
ProBioGen has been for a
while on a growth path. With
the formation of MiGenTra we
aim to further accelerate
our growth while
transforming the lives of
millions in urgent medical
need through
state-of-the-art medicines
at affordable prices. I am
honored to take on the CEO
position for this newly
built entity. We are
committed to contributing to
the transformational change
across healthcare in the
African continent."
Wafik Bardissi, PhD,
Chairman and Chief Executive
Officer of Minapharm
Pharmaceuticals added:
"MiGenTra marks a starting
point of practice to
consolidate an international
platform of intelligent
biopharmaceutical
technologies with a
longstanding regional
process development and
manufacturing expertise in
the Middle East and Africa.
Minapharm has demonstrated
the feasibility of aligning
economic interests and
equality in access to
affordable complex
genetically engineered
medicines. The COVID-19
pandemic has once again
exposed global inequalities
the world has ignored for
too long. MiGenTra pledges
to ensure equitable access
to essential medicines,
thereby contributing to the
Global Health Initiative."
Related Links:
MiGenTra
ProBioGen
Minapharm
Keywords:
Delivery of Health Care;
Vaccines; Biosimilar
Pharmaceuticals; Cell- and
Tissue-Based Therapy;
Manufacturing and Industrial
Facilities; Pharmaceutical
Preparations; Commerce;
Africa; Middle East; Egypt;
Germany
Source:
B3C newswire
PRINT
THIS ARTICLE
|
